Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY121 in Immunological Diseases (RAINBOW-LTE)
NCT06723106Phase 1Enrolling by invitation
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Feb 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 1, open-label, single-arm trial of RAY121 in antiphospholipid syndrome (APS), Bullous Pemphigoid (BP), Behçet's disease (BD) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Adverse Events at 52 weeks. Started Dec 2024; status: enrolling by invitation.
02
Drugs
RAY121
03
Conditions
antiphospholipid syndrome (APS)Bullous Pemphigoid (BP)Behçet's disease (BD)dermatomyositis (DM)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NCT06723106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723106.